Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Retained Earnings (2021 - 2026)

Zentalis Pharmaceuticals has reported Retained Earnings over the past 6 years, most recently at -$1.2 billion for Q1 2026.

  • For Q1 2026, Retained Earnings fell 11.26% year-over-year to -$1.2 billion; the TTM value through Mar 2026 reached -$1.2 billion, down 11.26%, while the annual FY2025 figure was $196000.0, 64.87% down from the prior year.
  • Retained Earnings for Q1 2026 was -$1.2 billion at Zentalis Pharmaceuticals, down from $196000.0 in the prior quarter.
  • Over five years, Retained Earnings peaked at $2.2 million in Q4 2023 and troughed at -$1.2 billion in Q1 2026.
  • A 5-year average of -$518.5 million and a median of -$596.4 million in 2022 define the central range for Retained Earnings.
  • Biggest five-year swings in Retained Earnings: skyrocketed 100.37% in 2023 and later plummeted 285925.15% in 2024.
  • Year by year, Retained Earnings stood at -$596.4 million in 2022, then skyrocketed by 100.37% to $2.2 million in 2023, then tumbled by 74.57% to $558000.0 in 2024, then crashed by 64.87% to $196000.0 in 2025, then tumbled by 626021.94% to -$1.2 billion in 2026.
  • Business Quant data shows Retained Earnings for ZNTL at -$1.2 billion in Q1 2026, $196000.0 in Q4 2025, and $186000.0 in Q3 2025.